PHARMACOGENETIC EVALUATION OF ANTI-HYPERTENSIVE RESPONSE (PEAR)

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的目的是确定大量基因与高血压患者对利尿剂和受体阻滞剂的反应之间的关系。该研究将验证以下假设：1)候选基因的多态性是患者间抗高血压差异和对b受体阻滞剂和噻嗪类利尿剂不良反应的重要决定因素；2)大量的新基因是患者间抗高血压差异和对b受体阻滞剂和噻嗪类利尿剂不良反应的重要决定因素。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine the association of a large number of genes with responses to diuretics and beta-blockers in hypertensive patients. It will test the hypothesis that 1) polymorphisms in proposed candidate genes are important determinants of the inter-patient variance in antihypertensive and adverse response to B-blockers and thiazide diuretics; and 2) there are a substantial number of new genes that are important determinants of the interpatient variance in antihypertensive and adverse responses to B-blockers and thiazide diuretics.